Lead Product(s) : Testosterone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 in Sarcopenia Treatment
Details : LPCN 1148 comprises testosterone dodecanoate, a unique androgen receptor agonist. It is being investigated for treatment for sarcopenia in patients with decompensated cirrhosis.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 17, 2024
Lead Product(s) : Testosterone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Testosterone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lipocine Reports Positive Week 52 Results from LPCN 1148 Phase 2 Study
Details : LPCN 1148 is a novel prodrug of an androgen receptor agonist, designed to improve liver and muscle function, enhance quality of life before liver transplant, and reduce hospital admissions.
Product Name : LPCN 1148
Product Type : Small molecule
Upfront Cash : Not Applicable
March 28, 2024
Lead Product(s) : Testosterone
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lybrido is a novel combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the PDE-5 inhibitor, sildenafil that used for the treatment of Female Sexual Interest/Arousal Disorder (FSIAD...
Product Name : Lybrido
Product Type : Small molecule
Upfront Cash : Not Applicable
June 19, 2023
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Testosterone
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lipocine Granted US Patents Directed To CNS And Liver Programs
Details : Testosterone Dodecanoate is steroid hormone, company filed patent for treatment of variety of diseases, such as CNS, cancer, Liver, Lung, Kidney, cardiovascular disease and endocrine disorders.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
June 14, 2022
Lead Product(s) : Testosterone
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Verity Pharma will promote NATESTO across the island of Puerto Rico, leveraging its existing commercial footprint and health care network. Acerus will maintain control of distribution, market access, and regulatory activ...
Product Name : Natesto
Product Type : Small molecule
Upfront Cash : Undisclosed
January 10, 2022
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Emotional Brain BV
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Freya Pharma has been established to further advance two compounds for the FSIAD-disorder, Lybrydo and Lybrydos, that have shown clinical and statistical relevance in an earlier phase 2b clinical trial, clearly meeting the primary endpoints.
Product Name : Lybrido
Product Type : Small molecule
Upfront Cash : Undisclosed
December 17, 2021
Lead Product(s) : Sildenafil Citrate,Testosterone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Emotional Brain BV
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Testosterone topical solution USP, 30 mg per pump actuation is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism and hypogonadotropic hypogonadism.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
June 16, 2021
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Testosterone,Anastrozole
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Clarus Therapeutics
Deal Size : $11.2 million
Deal Type : Licensing Agreement
Clarus Therapeutics and HavaH Therapeutics Announce Licensing Agreement
Details : CLAR-121 is a proprietary combination of testosterone (T) (natural ligand for the androgen receptor; AR) and anastrozole (inhibitor of T conversion to estradiol) delivered by a subcutaneous implant for treatment of AR-mediated breast disease that predomi...
Product Name : CLAR-121
Product Type : Small molecule
Upfront Cash : $0.5 million
May 25, 2021
Lead Product(s) : Testosterone,Anastrozole
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Clarus Therapeutics
Deal Size : $11.2 million
Deal Type : Licensing Agreement
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Acerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO®
Details : Under the terms of the agreement, Amneal will sell NATESTO, Testosterone Nasal gel to the company’s existing Endocrinology targets through June 30, 2024.
Product Name : Natesto
Product Type : Small molecule
Upfront Cash : Undisclosed
May 10, 2021
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Divestment
Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma
Details : Acerus will acquire all remaining rights to Natesto in the United States from Aytu. Acerus will assume all product responsibilities associated with Natesto.
Product Name : Natesto
Product Type : Small molecule
Upfront Cash : $7.5 million
April 01, 2021
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Divestment
Reset All
